Results 121 to 130 of about 929,917 (139)
American Journal of Nephrology, 2011 <i>Background/Aims:</i> Fibroblast growth factor-23 (FGF23) plays a central role in the development of hypophosphatemia and inappropriately low 1,25-dihydroxyvitamin D induced by iron therapy for iron-deficiency anemia. The aim of this study was to examine the effect of intravenous saccharated ferric oxide on serum FGF23 levels and mineral ...
Yoko, Takeda +9 more
openaire +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Effect of saccharated ferric oxide and iron dextran on the metabolism of phosphorus in rats
Translational Research, 2005As a means of investigating the physiologic damage to and histologic deterioration of the kidney caused by saccharated ferric oxide (SFO) and iron dextran (ID), we administered these substances intraperitoneally to rats. The rats were divided into 3 groups. Group 1 rats ( n = 7) were given SFO, 28 mg/kg for 9 days and 20 mg/kg for 19 days. Group 2 rats
Toru Sanai, Mitsuo Okada, Seiya Okuda
exaly +3 more sources
Bone, 1997
A 60-year-old man with portal hypertensive gastropathy due to type C liver cirrhosis developed severe bone pains, marked hypophosphatemia with inappropriately increased urinary excretion of phosphate (%TRP; 9.6%), and hyperalkaline phosphatasia, after intravenous administration of saccharated ferric oxide (SFO) at a dose of 80-240 mg/week over a period
H Demura
exaly +3 more sources
A 60-year-old man with portal hypertensive gastropathy due to type C liver cirrhosis developed severe bone pains, marked hypophosphatemia with inappropriately increased urinary excretion of phosphate (%TRP; 9.6%), and hyperalkaline phosphatasia, after intravenous administration of saccharated ferric oxide (SFO) at a dose of 80-240 mg/week over a period
H Demura
exaly +3 more sources
International Journal of Hematology, 2018
The intravenous formulation for supplementing iron currently available in Japan requires frequent administration. In contrast, ferric carboxymaltose (FCM) can improve iron-deficiency anemia (IDA) with only a small number of administrations; however, its efficacy and safety have not been established in Japanese patients.
Mikio Momoeda +2 more
exaly +3 more sources
The intravenous formulation for supplementing iron currently available in Japan requires frequent administration. In contrast, ferric carboxymaltose (FCM) can improve iron-deficiency anemia (IDA) with only a small number of administrations; however, its efficacy and safety have not been established in Japanese patients.
Mikio Momoeda +2 more
exaly +3 more sources
Stability of Saccharated Ferric Oxide during Dilution
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2020Junzo Kamei, Tomoya Abe
exaly +2 more sources
Hypophosphatemia induced by intravenous administration of saccharated ferric oxide
Bone, 2009Nobuaki Ito +2 more
exaly +2 more sources
Die Pharmazie, 2012
Over 90% of iron deficiency anemia cases are due to iron deficiency associated with depletion of stored iron or inadequate intake. Parenteral iron supplementation is an important part of the management of anemia, and some kinds of intravenous iron are used. However, few studies have evaluated the clinical efficacy of these drugs.
T, Araki +6 more
openaire +3 more sources
Over 90% of iron deficiency anemia cases are due to iron deficiency associated with depletion of stored iron or inadequate intake. Parenteral iron supplementation is an important part of the management of anemia, and some kinds of intravenous iron are used. However, few studies have evaluated the clinical efficacy of these drugs.
T, Araki +6 more
openaire +3 more sources
Bone, 2009
Fibroblast growth factor 23 (FGF23) is a humoral factor that is produced by osteocytes and regulates phosphate and vitamin D metabolism. Several hypophosphatemic diseases including X-linked, autosomal dominant and autosomal recessive hypophosphatemic rickets/osteomalacia and tumor-induced rickets/osteomalacia are caused by excess actions of FGF23 ...
Yuichiro, Shimizu +8 more
openaire +1 more source
Fibroblast growth factor 23 (FGF23) is a humoral factor that is produced by osteocytes and regulates phosphate and vitamin D metabolism. Several hypophosphatemic diseases including X-linked, autosomal dominant and autosomal recessive hypophosphatemic rickets/osteomalacia and tumor-induced rickets/osteomalacia are caused by excess actions of FGF23 ...
Yuichiro, Shimizu +8 more
openaire +1 more source
[Hokkaido igaku zasshi] The Hokkaido journal of medical science, 1982
In adult dd-mice, response of omental milk spots to colloidal saccharated ferric oxide intraperitoneally injected was observed by light and electron microscopy. Macrophages in milk spots and the fat tissue along the omental vessels took up large amounts of iron particles 1 hr after injection.
N, Takemori, T, Ito
openaire +1 more source
In adult dd-mice, response of omental milk spots to colloidal saccharated ferric oxide intraperitoneally injected was observed by light and electron microscopy. Macrophages in milk spots and the fat tissue along the omental vessels took up large amounts of iron particles 1 hr after injection.
N, Takemori, T, Ito
openaire +1 more source